CVS HEALTH Corp (CVS) Earnings History

CVS HEALTH Corp - Q4 FY2025 EarningsBeat

Filed at: Feb 10, 2026, 6:31 AM EST|Read from source

EXECUTIVE SUMMARY

CVS Health reported strong revenue growth for both the fourth quarter and full year 2025, driven by increases across all operating segments. However, profitability faced headwinds, with a significant decrease in GAAP operating income for the full year due to substantial goodwill impairment and litigation charges, alongside a decline in adjusted EPS for the quarter.

POSITIVE HIGHLIGHTS

  • •

    Total revenues increased 8.2% in Q4 2025 to $105.7 billion and 7.8% for the full year 2025 to a record $402.1 billion, driven by growth across all operating segments.

    positive
  • •

    Health Services segment adjusted operating income increased 9.2% in Q4 2025, driven by improved purchasing economics.

    positive
  • •

    Pharmacy & Consumer Wellness segment adjusted operating income increased 8.7% in Q4 2025, driven by increased prescription volume and favorable drug mix.

    positive
  • •

    Aetna® is improving the experience for health care professionals and patients, approving over 95% of eligible prior authorizations within 24 hours.

    neutral

CONCERNS & RISKS

  • •

    GAAP operating income decreased 10.8% in Q4 2025 and 45.3% for the full year 2025, primarily due to a $5.7 billion goodwill impairment charge and approximately $1.2 billion of legacy litigation charges in the full year.

    negative
  • •

    Adjusted EPS decreased by $0.10 to $1.09 in Q4 2025 compared to the prior year, primarily due to a decline in adjusted operating income in the Health Care Benefits segment.

    negative
  • •

    Health Care Benefits segment adjusted operating loss increased by $237 million in Q4 2025, driven by changes in Medicare Part D seasonality due to the IRA and unfavorable premium deficiency reserves.

    negative
  • •

    Health Services segment adjusted operating income decreased 1.3% for the full year 2025, primarily driven by continued pharmacy client price improvements.

    attention
  • •

    Medical membership as of December 31, 2025, decreased 504,000 members compared with December 31, 2024, reflecting declines in individual exchange and Government product lines.

    negative
  • •

    Updated cash flow from operations guidance for FY2026 to at least $9.0 billion from at least $10.0 billion.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$105.69B
+8.2%
Prior year: $97.71B
Annual (YTD)
$402.07B
N/A
Prior year: $372.81B
Net Income
Quarterly
$2.92B
0.0%
Prior year: $2.92B
EPS (Diluted)
Quarterly
$2.30
+76.9%
Prior year: $1.30
Operating Income
Quarterly
$2.11B
0.0%
Prior year: $2.11B
EPS (Basic)
Quarterly
N/A
N/A

MARGIN ANALYSIS

Operating Margin
Current Quarter
2.0%
Prior Year
2.4%
YoY Change
-42 bps
Net Margin
Current Quarter
2.8%
Prior Year
1.7%
YoY Change
+111 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

REVENUE BY SEGMENT — Q4 FY2025 2025

VISUAL OVERVIEW

|
Health Care Benefits
0.0%
N/A
Health Services
0.0%
N/A
Pharmacy & Consumer Wellness
0.0%
N/A

DETAILED BREAKDOWN

|
SegmentCurrentPrior YrYoY% Total
Health Care Benefits
N/A———
Health Services
N/A———
Pharmacy & Consumer Wellness
N/A———
Total Revenue$0.00M——100.0%

Segment performance shows business unit health and growth drivers.

MANAGEMENT GUIDANCE

FY2026

GAAP diluted EPS
$5.94—$6.14
Mid-point: $6.04
Adjusted EPS
$7.00—$7.20
Mid-point: $7.10

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

SPECIAL ITEMS & ADJUSTMENTS

FY2025
Goodwill impairment charge related to the Health Care Delivery reporting unit
Not deductible for income tax purposes.
+$5,725M
$4.50 per share
FY2025
Legacy litigation charges related to two court decisions
Includes $387M for Omnicare and $291M for PBM reporting practices.
+$1,220M
$0.96 per share
FY2025
Health Care Delivery clinic closure charge
+$83M
$0.07 per share
FY2025
Loss on Accountable Care assets (divestiture and wind-down)
+$288M
$0.23 per share
FY2024
Restructuring charges
Includes store impairment, corporate workforce optimization, and non-core asset impairments.
+$1,179M
$0.93 per share
FY2025
Opioid litigation charges
+$320M
$0.25 per share
FY2024
Opioid litigation charges
+$100M
$0.08 per share
Total Impact
+$8,915M$7.02 per share

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses.

— CVS HEALTH Corp, Q4 FY2025 2025 Earnings Call

From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.

— CVS HEALTH Corp, Q4 FY2025 2025 Earnings Call

CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.

— CVS HEALTH Corp, Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Medical membership
26.6M
-1.9% YoY
Prior year: 27.1M
members
Pharmacy claims processed
1900.7M
-0.9% YoY
Prior year: 1917.6M
30-day equivalents
Prescriptions filled
1808.8M
+5.4% YoY
Prior year: 1715.5M
30-day equivalents

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.